Healthcare Industry News: gastrointestinal stromal tumor
News Release - July 29, 2010
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & DevelopmentExperienced Industry Leader in Oncology Drug Development to Advance PI3K Pipeline
SEATTLE--(HSMN NewsFeed)--Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the appointment of Langdon L. Miller, M.D. as Executive Vice President, Research & Development.
A veteran leader in the biopharmaceutical industry, Dr. Miller brings more than two decades of drug development experience to Calistoga Pharmaceuticals. He has previously overseen the design and conduct of multiple registration-directed programs at PTC Therapeutics, Pharmacia, and the National Cancer Institute. He will lead the research and development team at Calistoga to advance CAL-101 into full development studies.
“Dr. Miller is an experienced and respected leader in drug development with a career spanning both corporate and academic positions and a track record of successful cancer therapy registrations,” said Carol Gallagher, Pharm. D., President and Chief Executive Officer. “We are very pleased to have Dr. Miller join our team to lead our full development efforts for CAL-101 and advance our isoform-selective PI3K inhibitor pipeline.”
Dr. Miller joins Calistoga Pharmaceuticals from PTC Therapeutics, where he served as Chief Medical Officer and led the strategic design and implementation of development activities for the company’s clinical-stage compounds. Prior to his time at PTC Therapeutics, Dr. Miller served as Vice President of Global Oncology Clinical Research at Pharmacia Corporation. At Pharmacia, Dr. Miller led multiple clinical research programs, including programs that culminated with the successful registrations of irinotecan for colorectal cancer, exemestane and epirubicin for breast cancer, and sunitinib for renal cell cancer and gastrointestinal stromal tumors. During this time, he was the primary or senior author of eight New Drug Applications (NDAs) and has led six presentations before the Food and Drug Administration's Oncologic Drugs Advisory Committee. Prior to his work at Pharmacia, Dr. Miller served as a senior investigator at the National Cancer Institute, providing strategic direction for NCI-sponsored trials that evaluated the use of colony-stimulating factors in hematological and other malignancies.
“The team at Calistoga Pharmaceuticals has made great progress in advancing a first-in-class pipeline of isoform-selective PI3K inhibitors,” said Dr. Miller. “The clinical data are very encouraging, and I look forward to leading the company’s efforts to advance these candidates as potential novel treatments for patients with cancer and inflammatory diseases.”
Dr. Miller has held clinical positions at Stanford University, the University of California at San Francisco, and the University of Minnesota. He received his B.S. from Northwestern University and his M.D. from Northwestern University Medical School.
Calistoga Pharmaceuticals’ lead product candidate, CAL-101, is an oral, delta-isoform-selective PI3K inhibitor. CAL-101 has demonstrated very promising single-agent anti-tumor activity in patients with hematologic malignancies and is targeted to enter registration trials in the near future. In addition to CAL-101, Calistoga Pharmaceuticals’ pipeline of isoform-selective PI3K inhibitors includes CAL-263, a delta-isoform-selective PI3K inhibitor that may have utility as a treatment for inflammatory diseases.
About Calistoga Pharmaceuticals
Calistoga Pharmaceuticals is dedicated to developing targeted therapy to improve the health of patients with cancer and inflammatory diseases. Calistoga Pharmaceuticals has a portfolio of proprietary compounds selectively targeting isoforms of the PI3K pathway. The Company’s most advanced compound, CAL-101, a selective PI3K delta inhibitor, is under clinical evaluation in patients with B-cell malignancies. Calistoga is a private company headquartered in Seattle, Washington. For more information, visit the Company’s website at: www.calistogapharma.com.
Source: Calistoga Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.